Differences in Severity of Poison Centers Exposures Involving XTAMPZA^® ER Versus Other Opioid Analgesics

Abstract

Aims: Xtampza^® ER (Collegium Pharmaceutical, MA, USA) is an abuse-deterrent formulation (ADF) of oxycodone intended to deter tampering for use by unintended routes of administration. We assessed whether Xtampza ER exposures were less likely to result in severe medical outcomes relative to other opioid analgesic exposures. Materials & methods: Exposures reported to participating poison centers between 2016 and 2021 inclusive that were followed to a known medical outcome were analyzed. Xtampza ER was compared with other ADF opioids, non-ADF extended-release opioids, single-entity oxycodone immediate-release, unspecified oxycodone and unspecified morphine. Results & conclusion: No Xtampza ER exposures involved unintended routes of administration. Xtampza ER exposures were less likely to be abuse, misuse or suspected suicidal, and medical outcomes were less severe than comparators.

Tweetable abstract

Xtampza ER exposures reported to poison centers tended to be less severe than comparators. Xtampza ER exposures were less likely to be classified as abuse, misuse or unknown intentional exposure than comparators. No Xtampza ER exposures involved injection or inhalation use.

Keywords::

• abuse
• abuse-deterrent formulations
• misuse
• opioids
• routes of administration

Financial & competing interests disclosure

This study was funded by Collegium Pharmaceutical.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The Poison Center Program study protocol received its most recent review and approval from the Colorado Multiple Institutional Review Board (COMIRB) on 30 April 2021. In addition, the study protocol was reviewed and approved by the Institutional Review Board of each participating poison center.

Supplementary data

Additional information

Funding

This study was funded by Collegium Pharmaceutical. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.